NeoGenomics, Inc. · NASDAQ:NEO
NeoGenomics — Investor Presentation (April 2012)
19 slides from NeoGenomics's investor presentation, April 2012

Slide 1: Company Overview Presentation
OTCBB: NGNM Time Matters. Results Count! Company Overview Presentation April 2012 “Improving Patient Care through exceptional cancer genetic testing services!” 1

Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “m

Slide 3: Investment Highlights
Investment Highlights • Fast growing pure-play, cancer genetics lab • Servicing: Oncologists, Pathologists and Hospitals • Innovative “Tech-Only” business model creates strategic partnerships with customers • Rapidly growing industry undergoing consolidation • Strong Management Team with large cap l

Slide 4: Consistent Historical Growth
Consistent Historical Growth Annual Revenue ($, 000s) Tests Performed $50,000 80,000 $40,000 60,000 $30,000 40,000 $20,000 $10,000 20,000 $0 0 4

Slide 5: Business Model Targets Two Customer Groups
Business Model Targets Two Customer Groups Pathologists and Hospital Path Groups: “Tech only” • Innovative technical component-only services – Flow, FISH, IHC • Enables community pathologists to compete with large labs • Rapid turnaround-time and web-based reporting • Extensive training programs Onc

Slide 6: Key Growth Drivers
Key Growth Drivers • Rapidly increasing sales force productivity • Penetration of increasingly larger customers • Tech-only model facilitates clinician office insourcing • Extensive and highly regarded education programs to train clients in “Genetic Pathology” • Rapid expansion of IHC capabilities •

Slide 7: Exclusive License Agreement with HDC
Exclusive License Agreement with HDC • Covers 84 patents and pending patents relating to pattern recognition technology, digital image analysis, biomarker discovery, and gene & protein-based tests • Unrestricted sublicensing and assignment rights • Success-based license structure - $3 MM in cash and

Slide 8: Advanced Molecular Genetics Services
Advanced Molecular Genetics Services Cytogenetics: chromosome analysis - “Neighborhood view of 46 houses from 1000 feet” Flow Cytometry: cell surface marker analysis - “Single house view from 500 feet” Fluorescence in-situ Hybridization (FISH): gene analysis - “Door and window view of one house” Mol

Slide 9: U.S. Cancer Testing Market: $10-12 Billion
U.S. Cancer Testing Market: $10-12 Billion Hematopoietic Solid Tumor Cancers Cancers Total Testing Market: $3 - 4 Billion $7 - 8 Billion Est. Genetic Mkt. (TAM) ~$1 - 2 Billion ~$1 - 2 Billion Patients in Treatment: 850,000 7.0 million New Diagnoses/Yr.: 150,000 1.45 million Specimen Types: Bone Mar

Slide 10: Boomer Impact on U.S. Cancer Market
Boomer Impact on U.S. Cancer Market 77% of all Cancers Diagnosed are in People Age 55 or Older, the Fastest Growing Segment of the US Population (American Cancer Society) 10

Slide 11: Cancer Testing Market Dynamics
Cancer Testing Market Dynamics • Highest growth segment of lab Industry - 20-25% annual growth in genetics testing - 8-10% annual growth in related AP testing • Approx. 360 Genetic Labs in the U.S. - 2/3 affiliated with academic institutions - Approximately 20% perform 80% of testing - Only 15-20 la

Slide 12: A Growing Landscape
A Growing Landscape VT WA ME MT ND MI MN NH OR NY MA ID SD WI RI WY MI PA CT IA NJ NE OH DE IL IN NV MD WV UT VA CO KS MO CA KY NC Nashville, TN OK AR SC 7k sf AZ NM AL GA MS LA TX Tampa, FL Irvine, CA FL 5k sf 18k sf States sending specimens Ft. Myers, FL 31k sf 12

Slide 13: Management Team
Management Team • Douglas VanOort, Chairman & CEO Operating Partner, Summer Street Capital Partners; Chief Operating Officer, Quest Diagnostics • Maher Albitar, M.D., Chief Medical Officer & Director of R&D Med. Dir. for Hematopathology & Oncology and Chief of R&D, Quest Nichols Institute; Director

Slide 14: Volume and Price Growth
Volume and Price Growth 26,932 27,000 $700 661 659 652 624 613 606 603 22,557 602 610 24,000 603 600 587 569 570 567 572 $600 552 563 534 523 21,000 493 522 572 504 509 19,977 479 484 449 18,358 $500 18,000 440 15,396 15,000 14,464 14,349 $400 14,042 14,477 12,714 12,000 11,31611,188 10,457 $300 9,4

Slide 15: Quarterly Revenue
Quarterly Revenue 15,160 $ 15,000 12,893 $ 12,000 11,320 10,466 8,804 8,708 8,755 $ 9,000 8,418 8,490 7,2977,799 7,459 6,914 5,920 $ 6,000 5,057 4,881 4,163 3,795 3,123 2,344 $ 3,000 2,243 1,6021,763 1,767 1,344 559 751 230 345 $0 Q1 05 Q2 05 Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4

Slide 16: Historical Financial Information
Historical Financial Information ($, 000's) 2007 2008 2009 2010 2011 Total Revenue $ 11,505 $ 20,015 $ 29,469 $ 34,371 $ 43,484 % Growth 78.0% 74.0% 47.2% 16.6% 26.5% % Growth Adjusted * 70.0% 25.4% 30.2% Gross Margin % 52.0% 53.3% 51.6% 45.9% 44.7% Sales & Marketing as a % of Rev 20.5% 16.8% 23.4%

Slide 17: Quarterly Financial Information
Quarterly Financial Information ($, 000's) Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Total Revenue $ 8,805 $ 10,466 $ 11,320 $ 12,893 $ 15,160 % Growth (YoY) 4.6% 23.3% 30.0% 47.3% 72.2% % Growth (YoY) - Adjusted* 11.4% 25.0% 32.0% 47.3% 72.2% Gross Margin 43.9% 44.5% 44.8% 45.2% 47.1% Sales & Marketing as a %

Slide 18: Key Financial Information
Key Financial Information Recent Share Price (4/24/2012): $ 1.70 Basic Shares Outstanding: 44.8 M Current Market Cap: $76.2 M Diluted Shares for Reporting (MRQ): 47.4 M Fully Diluted Shares: 53.0 M Public Float Shares: 35.0 M 52 Week High/Low: $0.96/$1.84 Avg. Daily Trading Volume (3 Mos): 30,991 18

Slide 19: NeoGenomics Summary
NeoGenomics Summary • Emerging leader in the fastest growing segment of the lab testing industry • Strong competitive advantages and product portfolio • Strong Management Team with directly relevant industry experience • Accelerating profitability through revenue growth and increased operating lever
Source: Internet Archive copy of neogenomics.com
More decks from NeoGenomics, Inc.
Q3 2026 Earnings Presentation26 slides · Oct 28, 2026
Q2 2026 Earnings Presentation24 slides · Jul 28, 2026
Q1 2026 Earnings Presentation27 slides · Apr 28, 2026
Q4 2025 Earnings Presentation15 slides · Feb 17, 2026
Q3 2025 Earnings Presentation17 slides · Oct 28, 2025
Q2 2025 Earnings Presentation17 slides · Jul 29, 2025